

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
31 August 2023 (31.08.2023)



(10) International Publication Number
WO 2023/164474 A1

(51) International Patent Classification:

A61P 35/00 (2006.01) C07K 16/28 (2006.01)
A61K 47/68 (2017.01) A61K 39/00 (2006.01)

(21) International Application Number:

PCT/US2023/063010

(22) International Filing Date:

22 February 2023 (22.02.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/313,119 23 February 2022 (23.02.2022) US
63/429,311 01 December 2022 (01.12.2022) US

(71) Applicant: **AMGEN INC.** [US/US]; One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US).

(72) Inventors: **HASHEMI SADRAEI**, Nooshin; c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US). **MINOCHA**, Mukul; c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US). **GOLDRICK**, Amanda; c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US). **CHEN**, Xi; c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US).

KISTLER, Mira; c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: CANCER TREATMENT TARGETING DLL3




Figure 1A

(57) Abstract: Invention disclosed herein provides a method for the treatment of DLL3-positive cancer or SCLC, comprising administering to a subject in need thereof an anti-DLL3 agent alone, or in combination with an anti-PD-L1 antibody and/or chemotherapeutic agents. Step dosing or extended IV infusion of the anti-DLL3 agent is also disclosed.

[Continued on next page]

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*